Search
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils
Categories: Interleukin-5 Receptor alpha-directed Cytolytic Antibody, Interleukin 5 Receptor alpha-directed Antibody InteractionsProducts: FASENRA®Gadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.
Categories: Compounds used in a research, industrial, or household settingTelotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsUlimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility … of the GI tract is severely impaired.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … a first-line treatment option in advanced ALK-positive NSCLC.
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: XOSPATA® FILM-COATED TABLETS 40MGGepirone
go.drugbank.com/drugs/DB12184Approvedside effects as that of the placebo. … Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingExatecan
go.drugbank.com/drugs/DB12185InvestigationalExatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.
Categories: Topoisomerase I Inhibitors